Burn Wound Clinical Trial
Official title:
A Clinical Evaluation of an Esterified Hyaluronic Acid Matrix on Preparing Wounds in Burn Patients for Split-thickness Skin Grafting
Verified date | November 2021 |
Source | Medline Industries |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Burn patients meeting inclusion criteria will receive the esterified hyaluronic acid matrix as the matrix for their wound, in conjunction with the standard of care for managing these types of wounds. The study will be divided into two phases. Phase I will entail intervention with the wound matrix and will continue until one of the following occur, sufficient granulation has occurred and the patient can receive a STSG and proceed to Phase II, the patient's physician determines an STSG is no longer necessary or two applications with the wound matrix occur and no STSG is approved. Phase II will begin following the STSG procedure. In this phase, the wound will be monitored and proportion of STSG take will be evaluated but no application of the wound matrix device will take place. This phase will continue for 28 days or if the physician deems the patient no longer needs regular care to monitor the wound, whichever occurs earlier.
Status | Terminated |
Enrollment | 5 |
Est. completion date | September 22, 2021 |
Est. primary completion date | September 22, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Has a wound originating from a thermal or electrical burn - Target burn area is less than 20% of TBSA - Target burn wound is greater than 0.5% of TBSA - Patient has undergone escharectomy procedure or will undergo escharectomy on the target burn and resulting wound will likely need a split thickness skin graft, but wound site is not immediately ready for grafting - For patients with diabetes, an A1C hemoglobin level between 11 percent (taken within 90 days) Exclusion Criteria: - Current active diagnosis of substance abuse, per the Investigator - Patient currently taking non-inhaled corticosteroids - Patient needs or is likely to need negative pressure wound therapy of the target wound after application of Hyalomatrix Wound Device - Patient is pregnant, planning to become pregnant during study period, or breastfeeding - Unstable medical condition as determined by the site investigator - Patients with known sensitivities to hyaluronan, hyaluronan derivatives, silicone, or any other ingredients of the Hyalomatrix Wound Device |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medline Industries |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Days From Initial Application of Wound Matrix to Approval of Wound to Receive a Split Thickness Skin Graft | Baseline to 42 days | ||
Secondary | Change in Wound Volume From the Time Prior to Application of the Wound Device to the Time Before the Application of STSG and After STSG | Baseline to 42 days | ||
Secondary | Length of Stay in Inpatient Unit | Baseline to 42 days | ||
Secondary | Patient Pain Rating | Baseline to 42 days | ||
Secondary | Proportion of Split Thickness Skin Graft Take for the Wound at 28 Days | 28 days | ||
Secondary | Proportion of Patients Who Develop an Infection of the Target Wound at Any Time Per Confirmation With Culture | Baseline to 70 days | ||
Secondary | Subject Discharge Destination | The facility that the subject is discharged to will be captured. | Baseline to 70 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03948360 -
Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds
|
N/A | |
Completed |
NCT04277182 -
Effect of Propolis Application on Burn Healing
|
N/A | |
Enrolling by invitation |
NCT00978705 -
Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood
|
Phase 3 | |
Withdrawn |
NCT03675568 -
Non-cultured Autologous Keratinocyte Suspension Versus Traditional Split Skin Graft for Burn Wounds Treatment
|
N/A | |
Active, not recruiting |
NCT04828304 -
PLASOMA Ultimate Safety & Efficacy Study
|
N/A | |
Not yet recruiting |
NCT05649332 -
Study to Evaluate the Performance and Safety of the Medical Device Argogen
|
N/A | |
Recruiting |
NCT05593523 -
Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes
|
||
Completed |
NCT06280053 -
HealiAid in the Treatment of Different Wounds
|
N/A | |
Enrolling by invitation |
NCT06103409 -
MSCs for the Treatment of Burn Wounds
|
Phase 1/Phase 2 | |
Recruiting |
NCT05796492 -
Ultrasound Treatment on Wound Healing Time
|
N/A | |
Enrolling by invitation |
NCT04725071 -
Immunonutrition Supplementation for Improved Burn Wound Healing in Older Adults
|
N/A | |
Suspended |
NCT02577120 -
Wound Healing Endpoint and Recurrence
|
Phase 4 | |
Active, not recruiting |
NCT05341427 -
DEVELOPMENT OF A CLINICAL PREDICTION RULES TO IDENTIFY EFFICACY OF PULSED ELECTROMAGNETIC THERAPY ON BURN WOUND HEALING
|
N/A | |
Completed |
NCT04753723 -
The Use of a Platform Wound Device for Reducing Infection
|
Phase 4 | |
Not yet recruiting |
NCT04011306 -
A Feasibility Study of a Novel Phototherapy System for the Management of Acute Burns
|
N/A | |
Recruiting |
NCT05404191 -
Prediction Rules for Low Level Laser on Burn Wounds
|
N/A | |
Completed |
NCT02982096 -
Study Comparing Healing With Epidermal Fractional Blistergrafting (CellutomeTM) to Acellular Technique
|
N/A |